Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant

Dermatologic Therapy

Volumn 27, Issue 3, 2014, Pages 178-182

  Jiménez Gallo, David ^a   Albarrán Planelles, Cristina ^a   Linares Barrios, Mario ^a   Fernández Anguita, María José ^a   Márquez Enríquez, Juan ^b   Rodríguez Mateos, María Eugenia ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^b HOSPITAL DE JEREZ   (Spain)

Author keywords

aprepitant; mycosis fungoides; pruritus

Indexed keywords

ALPHA2B INTERFERON; APREPITANT; CORTICOSTEROID; DOXEPIN; EBASTINE; HYDROXYZINE; INTERFERON; METHOTREXATE; NEUROKININ 1 RECEPTOR ANTAGONIST; PSORALEN; SUBSTANCE P; SUBSTANCE P RECEPTOR; ANTIPRURITIC AGENT; MORPHOLINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPOPIGMENTATION; HYPOPIGMENTED MYCOSIS FUNGOIDES; MEDICAL DOCUMENTATION; MYCOSIS FUNGOIDES; NAUSEA; PHYSICAL EXAMINATION; PRURITUS; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; VISUAL ANALOG SCALE; VOMITING; CANCER STAGING; COMPLICATION; PATHOLOGY; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; ANTIPRURITICS; FEMALE; HUMANS; HYPOPIGMENTATION; MORPHOLINES; MYCOSIS FUNGOIDES; NEOPLASM STAGING; NEUROKININ-1 RECEPTOR ANTAGONISTS; PRURITUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84902087264     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12113     Document Type: Article

References (13)

1. Weberschock T, Strametz R, Lorenz M, et al. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2012: (9): CD008946.
2. Ahern K, Gilmore ES, Poligone B,. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol 2012: 67: 760-768.
3. Vij A, Duvic M,. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012: 51: 930-934.
4. Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012: 13: 1020-1024.
5. Vincenzi B, Tonini G, Santini D,. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010: 363: 397-398.
6. Torres T, Fernandes I, Selores M, Alves R, Lima M,. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol 2012: 66: e14-e15.
7. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J,. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 2011: 164: 665-667.
8. Ladizinski B, Bazakas A, Olsen EA,. Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 2012: 67: e198-e199.
9. Duval A, Dubertret L,. Aprepitant as an antipruritic agent? N Engl J Med 2009: 361: 1415-1416.
10. Wallengren J,. Topical aprepitant in clinical and experimental pruritus. Arch Dermatol 2012: 148: 957-959.
11. Fischer A, Rosen AC, Ensslin CJ, Wu S, Lacouture ME,. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther 2013: 26: 135-148.
12. Werner B, Brown S, Ackerman AB,. "Hypopigmented mycosis fungoides" is not always mycosis fungoides! Am J Dermatopathol 2005: 27: 56-67.
13. Levesque N, Mitchinson K, Lawrie D, et al. Health management program: factors Influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. Curr Oncol 2008: 15: 36-41.